Related Experiment Video
Updated: Jan 7, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Psychological Impact of Newborn Screening for 3-Methylcrotonyl-CoA Carboxylase Deficiency: The Parental Experience
Vincenza Gragnaniello1, Giacomo Gaiga1, Chiara Cazzorla1
1Division of Inherited Metabolic Diseases, Department of Women's and Children's Health, University Hospital of Padua, 35128 Padua, Italy.
Insights
Newborn screening for 3-Methylcrotonyl-CoA carboxylase deficiency (3-MCCD) identifies affected infants early. Despite initial parental stress, long-term benefits like avoiding metabolic decompensation outweigh drawbacks.
Area of Science:
- Metabolic Disorders
- Newborn Screening
- Genetics
Background:
- 3-Methylcrotonyl-CoA carboxylase deficiency (3-MCCD) presents a variable clinical spectrum.
- Expanded newborn screening has identified many asymptomatic 3-MCCD cases, sparking debate on panel inclusion.
Purpose of the Study:
- To evaluate long-term outcomes of newborns with positive 3-MCCD screening results.
- To assess the psychological impact on parents of children with 3-MCCD.
Main Methods:
- Analysis of 336,668 newborns screened between 2014-2025.
- Annual clinical and biochemical assessments (acylcarnitine profile, carnitine, urinary organic acids).
- Parental psychological impact survey and emergency protocol for affected children.
Main Results:
- Nine infants confirmed with 3-MCCD; one experienced treated metabolic decompensation.
- One patient showed growth retardation, another transient psychomotor delay; five developed carnitine deficiency.
- Initial parental psychological impact decreased over time; all parents supported screening.
Conclusions:
- Newborn screening for 3-MCCD enables early identification and management, preventing severe decompensation.
- Long-term benefits of 3-MCCD newborn screening outweigh initial parental psychological burden.
- Screening is beneficial for managing 3-MCCD and its associated health risks.
Abstract:
3-Methylcrotonyl-CoA carboxylase deficiency (3-MCCD) is a metabolic disorder with a wide clinical spectrum ranging from asymptomatic individuals to severe metabolic decompensation. Following the introduction of expanded newborn screening, a high number of asymptomatic individuals with 3-MCCD were identified, prompting debates about its inclusion in screening panels. In order to inform policy and healthcare decisions regarding the inclusion of 3-MCCD in newborn screening programs, we evaluated the long-term outcomes for newborns with positive results over a decade of screening experience in North-East Italy, as well as the psychological impact on their parents. Of the 336,668 newborns screened between 2014 and 2025, 9 were confirmed to be affected. These infants underwent annual clinical and biochemical assessments, including dried blood spot acylcarnitine profile, plasma free carnitine, and urinary organic acids assays. An emergency protocol was provided to all affected children to manage intercurrent illnesses. An ad hoc survey was developed to assess the psychological impact of the disease on parents. During follow-up (mean age at last visit: 4.2 years), one patient experienced metabolic decompensation during an intercurrent illness, which was promptly treated. One patient presented with growth retardation and another with transient psychomotor delay. Five patients developed carnitine deficiency, requiring supplementation. Psychological assessments revealed an initial high level of parental psychological impact, which decreased over time. All parents strongly supported the screening program. Newborn screening for 3-MCCD enabled the early identification and management of affected individuals, thereby avoiding severe metabolic decompensation. Although there is an initial psychological burden on parents, it significantly decreases over time. Therefore, the long-term benefits of newborn screening for 3-MCCD seem to outweigh the psychological drawbacks.
Related Concept Videos
Pedigree Analysis
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Relationship with Parents: Attachment
Inborn Errors of Metabolism

